LEIDEN, THE NETHERLANDS--(Marketwire - January 27, 2012) - OctoPlus N.V. ("OctoPlus", or the "Company") (AMS: OCTO) publishes today a prospectus for the admission to listing and trading on Euronext Amsterdam by NYSE Euronext ("Euronext Amsterdam") of 8,000,000 newly issued ordinary shares as per 27 January 2012 (the "Prospectus"). The shares were issued in the context of the private placement that OctoPlus successfully completed on 31 October 2011 which raised EUR 4.0 million gross from new and existing investors (the "Offering"). The proceeds of this financing will be used for working capital purposes and for high value opportunities with upside potential such as specialty generics.
It should be noted that the Prospectus contains a qualified working capital statement which states that OctoPlus has not secured sufficient working capital for its present requirements, being the next 12 months from the date of this Prospectus. The company has a gradually improving negative operational cash flow, continuing during the first half of 2012. The Company is confident that it will be able to generate sufficient funds to continue its business for the next 12 months from the date of this Prospectus by its mitigating action plan, as further detailed in the Prospectus. The Prospectus was approved by the Netherlands Authority for the Financial Markets (AFM) on 24 January 2012. The Prospectus is available in the Investor Relations section on the Company's website: www.octoplus.nl.
Financial calendar 2012
OctoPlus also announces that it will publish its annual results for the year 2011 on Friday 17 February, which will be discussed in a conference call and webcast at 10:00 AM that day.
OctoPlus is a specialty pharmaceutical company focused on the development and manufacture of improved injectable pharmaceuticals based on our proprietary drug delivery technologies that exhibit fewer side effects, improved patient convenience and a better efficacy/safety balance than existing therapies. OctoPlus also focuses on the development of long-acting, controlled release versions of known protein therapeutics, peptides and small molecules, including specialty generics.
The clinically most advanced product incorporating our technology is Locteron®, a controlled release formulation of interferon alpha for the treatment of chronic hepatitis C. OctoPlus licensed Locteron exclusively to Biolex in October 2008. Locteron is being manufactured for Biolex by OctoPlus and has recently completed Phase IIb clinical studies with superior clinical data versus current treatment.
In addition, OctoPlus is a leading European provider of advanced drug formulation and clinical scale manufacturing services to the pharmaceutical and biotechnology industries, with a focus on difficult-to-formulate active pharmaceutical ingredients.
OctoPlus is listed on NYSE Euronext in Amsterdam under the symbol OCTO. For more information about OctoPlus, please visit our website www.octoplus.nl.
This document may contain certain forward-looking statements relating to the business, financial performance and results of OctoPlus and the industry in which it operates. These statements are based on OctoPlus' current plans, estimates and projections, as well as its expectations of external conditions and events. In particular the words "expect", "anticipate", "predict", "estimate", "project", "plan", "may", "should", "would", "will", "intend", "believe" and similar expressions are intended to identify forward-looking statements. We caution investors that a number of important factors, and the inherent risks and uncertainties that such statements involve, could cause actual results or outcomes to differ materially from those expressed in any forward-looking statements. In the event of any inconsistency between an English version and a Dutch version of this document, the English version will prevail over the Dutch version.